{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:50:26Z","timestamp":1791921026679,"version":"4.3.4"},"reference-count":70,"publisher":"Tech Science Press","issue":"6","license":[{"start":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T00:00:00Z","timestamp":1716422400000},"content-version":"vor","delay-in-days":143,"URL":"https:\/\/doi.org\/10.32604\/TSP-CROSSMARKPOLICY"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["OR"],"published-print":{"date-parts":[[2024]]},"DOI":"10.32604\/or.2024.047257","type":"journal-article","created":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T06:44:43Z","timestamp":1714027483000},"page":"1093-1107","update-policy":"https:\/\/doi.org\/10.32604\/tsp-crossmarkpolicy","source":"Crossref","is-referenced-by-count":10,"title":["Reversal of tamoxifen resistance by artemisinin in ER+ breast cancer: bioinformatics analysis and experimental validation"],"prefix":"10.32604","volume":"32","author":[{"given":"ZHILI","family":"ZHUO","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DONGNI","family":"ZHANG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"WENPING","family":"LU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"XIAOQING","family":"WU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YONGJIA","family":"CUI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"WEIXUAN","family":"ZHANG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MENGFAN","family":"ZHANG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"17807","published-online":{"date-parts":[[2024]]},"reference":[{"key":"ref1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA: A Cancer Journal For Clinicians"},{"key":"ref2","first-page":"438","article-title":"Breast cancer statistics","volume":"69","author":"DeSantis","year":"2019","journal-title":"2019 CA: A Cancer Journal For Clinicians"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1056\/NEJMoa2104162","article-title":"Duration of adjuvant aromatase-inhibitor therapy in postmenopausal breast cancer","volume":"385","author":"Gnant","year":"2021","journal-title":"The New England Journal of Medicine"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1604700","article-title":"Extending aromatase-inhibitor adjuvant therapy to 10 years","volume":"375","author":"Goss","year":"2016","journal-title":"The New England Journal of Medicine"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"4071","DOI":"10.1200\/JCO.21.02844","article-title":"Twenty-year benefit from adjuvant goserelin and tamoxifen in premenopausal patients with breast cancer in a controlled randomized clinical trial","volume":"40","author":"Johansson","year":"2022","journal-title":"Journal of Clinical Oncology"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"23","DOI":"10.21037\/tcr.2018.12.27","article-title":"Tamoxifen side effects: Pharmacogenetic and clinical approach in Mexican mestizos","volume":"8","author":"Rangel-M\u00e9ndez","year":"2019","journal-title":"Translational Cancer Research"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S1470-2045(21)00758-0","article-title":"Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: A patient-level meta-analysis of 7030 women from four randomised trials","volume":"23","year":"2022","journal-title":"The Lancet Oncology"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","article-title":"20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years","volume":"377","author":"Pan","year":"2017","journal-title":"The New England Journal of Medicine"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ccell.2020.03.009","article-title":"Overcoming endocrine resistance in breast cancer","volume":"37","author":"Hanker","year":"2020","journal-title":"Cancer Cell"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"djv212","DOI":"10.1093\/jnci\/djv212","article-title":"Enhancing endocrine therapy for hormone receptor-positive advanced breast cancer: Cotargeting signaling Pathways","volume":"107","author":"Johnston","year":"2015","journal-title":"Journal of the National Cancer Institute"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.drup.2015.11.001","article-title":"Treatment strategies for advanced hormone receptor-positive and human epidermal growth factor 2-negative breast cancer: The role of treatment order","volume":"24","author":"Perez","year":"2016","journal-title":"Drug Resistance Updates"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13058-018-1020-0","article-title":"NOTCH3 expression is linked to breast cancer seeding and distant metastasis","volume":"20","author":"Leontovich","year":"2018","journal-title":"Breast Cancer Research"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1038\/s41388-018-0656-7","article-title":"A Sox2-Sox9 signalling axis maintains human breast luminal progenitor and breast cancer stem cells","volume":"38","author":"Domenici","year":"2019","journal-title":"Oncogene"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1001\/jama.2022.12366","article-title":"Diagnosis, treatment, and prevention of malaria in the US: A review","volume":"328","author":"Daily","year":"2022","journal-title":"JAMA"},{"key":"ref15","first-page":"1386","article-title":"Evidence of artemisinin-resistant malaria in Africa. Reply","volume":"386","author":"Mita","year":"2022","journal-title":"The New England Journal of Medicine"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"107650","DOI":"10.1016\/j.pharmthera.2020.107650","volume":"216","author":"Feng","year":"2020","journal-title":"Pharmacology & Therapeutics"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"4986","DOI":"10.3390\/ijms21144986","volume":"21","author":"Septembre-Malaterre","year":"2020","journal-title":"International Journal of Molecular Sciences"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1186\/s13046-018-0960-7","article-title":"Artemisinin derivatives inactivate cancer-associated fibroblasts through suppressing TGF-\u03b2 signaling in breast cancer","volume":"37","author":"Yao","year":"2018","journal-title":"Journal of Experimental & Clinical Cancer Research: CR"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"600487","DOI":"10.3389\/fonc.2020.600487","article-title":"Comprehensive transcriptomic analysis reveals dysregulated competing endogenous RNA network in endocrine resistant breast cancer cells","volume":"10","author":"Gao","year":"2020","journal-title":"Frontiers in Oncology"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"4111","DOI":"10.1200\/JCO.2010.28.4273","article-title":"Genomic index of sensitivity to endocrine therapy for breast cancer","volume":"28","author":"Symmans","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"e107333","DOI":"10.15252\/embj.2020107333","article-title":"A single-cell RNA expression atlas of normal, preneoplastic and tumorigenic states in the human breast","volume":"40","author":"Pal","year":"2021","journal-title":"The EMBO Journal"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/nature03664","article-title":"Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma","volume":"436","author":"Garraway","year":"2005","journal-title":"Nature"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1093\/nar\/gkv007","article-title":"limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Research"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1186\/1471-2105-9-559","article-title":"WGCNA: An R package for weighted correlation network analysis","volume":"9","author":"Langfelder","year":"2008","journal-title":"BMC Bioinformatics"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1192777","DOI":"10.3389\/fphar.2023.1192777","article-title":"A novel T-cell exhaustion-related feature can accurately predict the prognosis of OC patients","volume":"14","author":"Yuan","year":"2023","journal-title":"Frontiers in Pharmacology"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1089\/omi.2011.0118","article-title":"clusterProfiler: An R package for comparing biological themes among gene clusters","volume":"16","author":"Yu","year":"2012","journal-title":"OMICS: A Journal of Integrative Biology"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1093\/bioinformatics\/btu684","article-title":"DOSE: An R\/Bioconductor package for disease ontology semantic and enrichment analysis","volume":"31","author":"Yu","year":"2015","journal-title":"Bioinformatics"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1471-2105-14-7","article-title":"GSVA: Gene set variation analysis for microarray and RNA-seq data","volume":"14","author":"Hanzelmann","year":"2013","journal-title":"BMC Bioinformatics"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"687975","DOI":"10.3389\/fimmu.2021.687975","article-title":"IOBR: Multi-omics immuno-oncology biological research to decode tumor microenvironment and signatures","volume":"12","author":"Zeng","year":"2021","journal-title":"Frontiers in Immunology"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nmeth.3337","article-title":"Robust enumeration of cell subsets from tissue expression profiles","volume":"12","author":"Newman","year":"2015","journal-title":"Nature Methods"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1263329","DOI":"10.3389\/fimmu.2023.1263329","article-title":"Combining single-cell sequencing and spatial transcriptome sequencing to identify exosome-related features of glioblastoma and constructing a prognostic model to identify BARD1 as a potential therapeutic target for GBM patients","volume":"14","author":"Zhao","year":"2023","journal-title":"Frontiers in Immunology"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.1021\/acs.jcim.1c00203","article-title":"AutoDock vina 1.2.0: New docking methods, expanded force field, and python bindings","volume":"61","author":"Eberhardt","year":"2021","journal-title":"Journal of Chemical Information and Modeling"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/s41574-021-00487-0","article-title":"Metabolic pathways in obesity-related breast cancer","volume":"17","author":"Brown","year":"2021","journal-title":"Nature Reviews Endocrinology"},{"key":"ref34","first-page":"378","article-title":"Obesity and adverse breast cancer risk and outcome: Mechanistic insights and strategies for intervention","volume":"67","author":"Picon-Ruiz","year":"2017","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.1200\/JCO.2017.73.4947","article-title":"Impact of preexisting mental illness on all-cause and breast cancer-specific mortality in elderly patients with breast cancer","volume":"35","author":"Iglay","year":"2017","journal-title":"Journal of Clinical Oncology"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.annonc.2021.07.005","article-title":"CYP2D6 genotype predicts tamoxifen discontinuation and drug response: A secondary analysis of the KARISMA trial","volume":"32","author":"He","year":"2021","journal-title":"Annals of Oncology"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.ccell.2021.03.010","article-title":"Targeting cell-cycle machinery in cancer","volume":"39","author":"Suski","year":"2021","journal-title":"Cancer Cell"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"e2002054","DOI":"10.1002\/adma.202002054","article-title":"Engineering macrophages for cancer immunotherapy and drug delivery","volume":"32","author":"Xia","year":"2020","journal-title":"Advanced Materials"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s12253-013-9740-z","article-title":"Tumor-associated macrophages are correlated with tamoxifen resistance in the postmenopausal breast cancer patients","volume":"20","author":"Xuan","year":"2014","journal-title":"Pathology Oncology Research"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41419-021-03781-x","article-title":"Sodium\/glucose cotransporter 1-dependent metabolic alterations induce tamoxifen resistance in breast cancer by promoting macrophage M2 polarization","volume":"12","author":"Niu","year":"2021","journal-title":"Cell Death & Disease"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"107706","DOI":"10.1016\/j.pharmthera.2020.107706","article-title":"Artemisinins as a novel anti-cancer therapy: Targeting a global cancer pandemic through drug repurposing","volume":"216","author":"Augustin","year":"2020","journal-title":"Pharmacology & Therapeutics"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1002\/cmdc.202000174","article-title":"Synthesis of tamoxifen-artemisinin and estrogen-artemisinin hybrids highly potent against breast and prostate cancer","volume":"15","author":"Frohlich","year":"2020","journal-title":"ChemMedChem"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S1470-2045(05)70388-0","article-title":"Modulation of cytochrome P450 activity: Implications for cancer therapy","volume":"6","author":"Scripture","year":"2005","journal-title":"The Lancet Oncology"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1136\/gutjnl-2014-308379","article-title":"Insulin resistance alters hepatic ethanol metabolism: Studies in mice and children with non-alcoholic fatty liver disease","volume":"65","author":"Engstler","year":"2016","journal-title":"Gut"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.annonc.2020.12.008","article-title":"A prospective study of type 2 diabetes, metformin use, and risk of breast cancer","volume":"32","author":"Park","year":"2021","journal-title":"Annals of Oncology"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"i5519","DOI":"10.1136\/bmj.i5519","article-title":"Glucagon-like peptide-1 receptor agonists and risk of breast cancer","volume":"355","author":"Bolen","year":"2016","journal-title":"BMJ"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"120370","DOI":"10.1016\/j.lfs.2022.120370","article-title":"Glucagon-like peptide-1 receptor activation by liraglutide promotes breast cancer through NOX4\/ROS\/VEGF pathway","volume":"294","author":"Liu","year":"2022","journal-title":"Life Sciences"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.ccr.2014.02.025","article-title":"ERBB receptors: From oncogene discovery to basic science to mechanism-based cancer therapeutics","volume":"25","author":"Arteaga","year":"2014","journal-title":"Cancer Cell"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/nature18003","article-title":"Proteogenomics connects somatic mutations to signalling in breast cancer","volume":"534","author":"Mertins","year":"2016","journal-title":"Nature"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/s41422-018-0079-6","article-title":"Imbalance of the reciprocally inhibitory loop between the ubiquitin-specific protease USP43 and EGFR\/PI3K\/AKT drives breast carcinogenesis","volume":"28","author":"He","year":"2018","journal-title":"Cell Research"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s13045-020-00949-4","article-title":"The MAPK and AMPK signalings: Interplay and implication in targeted cancer therapy","volume":"13","author":"Yuan","year":"2020","journal-title":"Journal of Hematology & Oncology"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1200\/JCO.19.02309","article-title":"Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP guideline update","volume":"38","author":"Allison","year":"2020","journal-title":"Journal of Clinical Oncology"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.pharmthera.2017.02.033","article-title":"Monoglyceride lipase as a drug target: At the crossroads of arachidonic acid metabolism and endocannabinoid signaling","volume":"175","author":"Grabner","year":"2017","journal-title":"Pharmacology & Therapeutics"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1038\/s41418-020-0549-5","article-title":"Monoglyceride lipase mediates tumor-suppressive effects by promoting degradation of X-linked inhibitor of apoptosis protein","volume":"27","author":"Liu","year":"2020","journal-title":"Cell Death and Differentiation"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1158\/0008-5472.CAN-18-3842","article-title":"Retinoic acid-related orphan receptor c regulates proliferation, glycolysis, and chemoresistance via the PD-L1\/ITGB6\/STAT3 signaling axis in bladder cancer","volume":"79","author":"Cao","year":"2019","journal-title":"Cancer Research"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12916-018-1010-1","article-title":"Circadian pathway genetic variation and cancer risk: Evidence from genome-wide association studies","volume":"16","author":"Mocellin","year":"2018","journal-title":"BMC Medicine"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s13045-021-01187-y","article-title":"Neutrophils in cancer carcinogenesis and metastasis","volume":"14","author":"Xiong","year":"2021","journal-title":"Journal of Hematology & Oncology"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1001\/jamaoncol.2015.0851","article-title":"The dual role of tumor-infiltrating lymphocytes in human epidermal growth factor receptor 2-positive primary breast cancer: Two sides of the same coin?","volume":"1","author":"Loibl","year":"2015","journal-title":"JAMA Oncology"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","article-title":"Tumour heterogeneity and resistance to cancer therapies","volume":"15","author":"Dagogo-Jack","year":"2018","journal-title":"Nature Reviews Clinical Oncology"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1093\/annonc\/mdy025","article-title":"Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer","volume":"29","author":"Hartmaier","year":"2018","journal-title":"Annals of Oncology"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1001\/jamaoncol.2016.1279","article-title":"Prevalence of ESR1 mutations in cell-free DNA and outcomes in metastatic breast cancer: A secondary analysis of the BOLERO-2 clinical trial","volume":"2","author":"Chandarlapaty","year":"2016","journal-title":"JAMA Oncology"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrclinonc.2015.117","article-title":"ESR1 mutations-a mechanism for acquired endocrine resistance in breast cancer","volume":"12","author":"Jeselsohn","year":"2015","journal-title":"Nature Reviews Clinical Oncology"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1158\/1078-0432.CCR-21-3185","article-title":"Modulation of the estrogen\/erbB2 receptors cross-talk by CDK4\/6 inhibition triggers sustained senescence in estrogen receptor- and erbB2-positive breast cancer","volume":"28","author":"Vigano","year":"2022","journal-title":"Clinical Cancer Research"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1001\/jamaoncol.2016.4975","article-title":"Androgen receptor function and androgen receptor-targeted therapies in breast cancer: A review","volume":"3","author":"Kono","year":"2017","journal-title":"JAMA Oncology"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/s41591-020-01168-7","article-title":"The androgen receptor is a tumor suppressor in estrogen receptor-positive breast cancer","volume":"27","author":"Hickey","year":"2021","journal-title":"Nature Medicine"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1038\/emboj.2009.290","volume":"28","author":"Williams","year":"2009","journal-title":"The EMBO Journal"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/s13046-018-0880-6","article-title":"HSP90AA1-mediated autophagy promotes drug resistance in osteosarcoma","volume":"37","author":"Xiao","year":"2018","journal-title":"Journal of Experimental & Clinical Cancer Research"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"R62","DOI":"10.1186\/bcr3168","article-title":"Amplification and high-level expression of heat shock protein 90 marks aggressive phenotypes of human epidermal growth factor receptor 2 negative breast cancer","volume":"14","author":"Cheng","year":"2012","journal-title":"Breast Cancer Research and Treatment"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s10549-015-3609-7","article-title":"Androgen receptor promotes tamoxifen agonist activity by activation of EGFR in ER\u03b1-positive breast cancer","volume":"154","author":"Ciupek","year":"2015","journal-title":"Breast Cancer Research and Treatment"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ctrv.2017.09.006","article-title":"Androgen receptor in estrogen receptor positive breast cancer: Beyond expression","volume":"61","author":"Basile","year":"2017","journal-title":"Cancer Treatment Reviews"}],"container-title":["Oncology Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.techscience.com\/files\/or\/2024\/TSP_OR-32-6\/OncolRes-32-06-47257\/OncolRes-32-47257.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T09:20:59Z","timestamp":1741252859000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.techscience.com\/or\/v32n6\/56597"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":70,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024]]},"published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.32604\/or.2024.047257","relation":{},"ISSN":["1555-3906"],"issn-type":[{"value":"1555-3906","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]},"assertion":[{"value":"2023-10-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-31","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-23","order":2,"name":"published","label":"Published Online","group":{"name":"publication_history","label":"Publication History"}}]}}